Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats.
about
Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.Adenosine A2A receptors and basal ganglia physiologyCoffee, Genetic Variants, and Parkinson's Disease: Gene-Environment InteractionsMetabotropic glutamate receptors in the basal ganglia motor circuitAdenosine A(2A) receptors and their role in drug addictionG protein-coupled receptor heterocomplexes in neuropsychiatric disorders.Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.Cue-conditioned alcohol seeking in rats following abstinence: involvement of metabotropic glutamate 5 receptors.Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.Theoretical considerations on the topological organization of receptor mosaicsProtective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP.Pathophysiological roles for purines: adenosine, caffeine and urate.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Adenosine A2A receptor in the monkey basal ganglia: ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum.Role of adenosine in the control of homosynaptic plasticity in striatal excitatory synapses.Local glutamate level dictates adenosine A2A receptor regulation of neuroinflammation and traumatic brain injuryGlutamate receptors as therapeutic targets for Parkinson's disease.Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells.Tuning and fine-tuning of synapses with adenosine.Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease.Advances in non-dopaminergic treatments for Parkinson's diseaseMavoglurant as a treatment for Parkinson's disease.Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease.Is the functional interaction between adenosine A(2A) receptors and metabotropic glutamate 5 receptors a general mechanism in the brain? Differences and similarities between the striatum and the hippocampus.A critical role of striatal A2A R-mGlu5 R interactions in modulating the psychomotor and drug-seeking effects of methamphetamine.mGlu5 Receptor Functional Interactions and AddictionAntiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder.The dopamine and cAMP regulated phosphoprotein, 32 kDa (DARPP-32) signaling pathway: a novel therapeutic target in traumatic brain injury.Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease.Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartate effects.Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches.Evaluation of four pyridine analogs to characterize 6-OHDA-induced modulation of mGluR5 function in rat brain using microPET studies.In silico studies targeting G-protein coupled receptors for drug research against Parkinson's disease.Targeting mGlu5 Metabotropic Glutamate Receptors in the Treatment of Cognitive Dysfunction in a Mouse Model of Phenylketonuria.Antiparkinsonian Effects of Novel Adenosine A2A Receptor Antagonists
P2860
Q24630645-D945CBDD-F82A-4FE1-86F6-0F0FC76B31E7Q24669783-64F17E20-0B94-47E9-A3BE-F08679F6EC50Q26852456-87CA113F-F734-42B6-BF0A-1BF7D3AFEF34Q28280931-914B225A-D59B-412D-9D5E-6C62FF364398Q28298915-C8B85D12-5293-4A94-9F4F-59B7EFA38DBDQ30385233-A02C70C1-CE1D-436A-9D14-09D3BD63A01AQ30482913-7AA52E22-F773-4D77-9D93-09EB90C66A0EQ33685890-42661EF1-DA3A-4266-8F93-B46262386CEAQ33754643-830FFCC6-8BD5-4B5B-BBB1-66F965FBA8B0Q33971113-8F3C9C90-A71E-4398-A66B-AC1E1509B24CQ34171499-8C9ECCFB-2607-43E9-B081-C5775758B22DQ34269340-55B193C3-361C-4393-BE80-3943A3D02692Q34564332-E3A5B07F-68BA-452C-9E53-FA61CCE8DAB2Q35008049-68A5EDBF-FEA1-4D22-BE02-8825D54F0ED2Q35614156-B81E91E8-8F32-4B2B-BC02-3A20C058893FQ35917127-C7E869A8-E64E-40F1-9129-4F485C1A1633Q36356787-69A00F2B-E64A-4DA6-A664-4DF1B6574BEBQ37347604-1A9B158F-6E67-4314-A657-C4BDAC694748Q37585401-17A438FF-C78B-4717-BA4A-94180EB02343Q37587515-2A37E90E-C0D0-44A5-922C-BCF31DD6ACD9Q37700201-78D76BF5-1133-4B2D-BAF8-B93B71DB51D3Q37844573-CB0012D8-E2A5-4AFA-B70B-029E5FF13548Q38092819-D7517DC1-356D-45DF-B6D6-DE192F3B3B55Q38174986-60E1C96E-2759-45A8-AA39-1B0511661784Q38218083-1668751A-AC88-4393-8ABF-85683E2392DCQ38222814-D00B72BA-BFA9-42E6-ADC7-7B57811B3062Q38285126-5C645BC1-B8AC-4565-A8B4-35D31D5738FFQ40726362-ABBDD62D-9640-479B-806B-856106F45516Q40939252-82C1C201-7977-4BB5-9E34-6E21FD918849Q41943753-C84BACD2-DB7A-46AA-96E3-32C9384631DBQ42372900-F0708B64-37CF-41FF-94ED-559A0353D8EFQ42749859-6852ADC0-C5C0-4427-B086-BFFFB9BD3D50Q46428813-0F92C824-197F-4F62-A5D5-5E983D92958FQ46791403-7D550FA8-B2F0-48E8-9879-BCCEFC66DB41Q47137101-A5F57E04-CAF2-4931-A8AA-D3D915377D69Q48273518-F40F47D4-3B23-4198-A6B3-DCFBD7661DC9Q52665081-6E9CDEE8-D674-4FD4-A170-CDF8963A91EBQ55352164-B98165B1-D68E-490D-B7EE-9F7D20D00D5FQ57708302-DA621FE1-F0A2-4286-A3AF-0AB834343DEA
P2860
Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Simultaneous blockade of adeno ...... Parkinsonian deficits in rats.
@en
Simultaneous blockade of adeno ...... Parkinsonian deficits in rats.
@nl
type
label
Simultaneous blockade of adeno ...... Parkinsonian deficits in rats.
@en
Simultaneous blockade of adeno ...... Parkinsonian deficits in rats.
@nl
prefLabel
Simultaneous blockade of adeno ...... Parkinsonian deficits in rats.
@en
Simultaneous blockade of adeno ...... Parkinsonian deficits in rats.
@nl
P2860
P356
P1476
Simultaneous blockade of adeno ...... Parkinsonian deficits in rats
@en
P2093
Nathalie Breysse
P2860
P2888
P304
P356
10.1038/SJ.NPP.1300444
P407
P577
2004-08-01T00:00:00Z